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Dear Editor,
We thank Dr Yoshida for his valuable comments and inter-
est in our study which describes the anti-cancer activity 
of DS00329, a novel derivative of the anti-psychotic drug 
phenothiazine, in glioblastoma multiforme (GBM) [1]. We 
appreciate the information provided by Dr Yoshida that 
illustrates that the activation of autophagy is an important 
mechanism by which neurochemical compounds and dopa-
mine receptor D4 antagonists inhibit GBM proliferation [2]. 
Furthermore, we agree with him that levels of p62/SQSTM1 
is an important indicator of the autophagic state of cells 
and that, in addition to our results showing an increase in 
LC3-11, it would be important to determine the impact of 
DS00329 on p62/SQSTM1 levels in glioblastoma cells. 
Indeed, increased LC3‐II levels can be associated with either 
enhanced autophagosome synthesis or reduced autophago-
some turnover. Thus, to differentiate between these two 
processes, it is important to determine the levels of p62/
SQSTM1 because it is a receptor of polyubiquinated pro-
teins and upon autophagy induction, p62/SQSTM1 is incor-
porated within an autophagosome and degraded within an 
autolysosome [3]. The degradation of p62/SQSTM1 is thus 
an indication of autophagic flux. Since the publication of 
our manuscript, we have confirmed that DS00329 treat-
ment results in decreased levels of p62/SQSTM1 and thus 
autophagic flux in the U87 and U251 glioblastoma cells. 
Furthermore, we agree with Dr Yoshida that the Acrid-
ine Orange stain alone may not be enough to differentiate 
autophagosomes from lysosomes as well as autolysosomes. 
However, this stain together with results showing a reduc-
tion in p62/SQSTM1 levels provide evidence that autophagic 
cargoes are being transferred to the lysosomes for degrada-
tion. Importantly, the antipsychotic phenothiazines, thiori-
dazine and chlorpromazine have also been shown to induce 
autophagic cell death in glioblastoma [4, 5]. Indeed electron 
microscopy of chlorpromazine treated cells showed large 
vacuoles containing cargoes, indicative of autophagic flux 
[4].
In our manuscript we showed that DS00329 induces DNA 
damage and apoptotic and autophagic cell death in U87 and 
U251 glioblastoma cells and we are currently investigat-
ing the signalling pathways involved. We thus agree with 
Dr Yoshida that as part of these investigations we should 
explore the impact of DS00329 on the c-Jun N-terminal 
kinase (JNK) and p38 MAP kinase pathways because of 
their roles in autophagic cell death and the DNA damage 
pathway respectively. Indeed, our preliminary data show that 
DS00329 activates the p38 MAP kinase pathway in U87 and 
U251 glioblastoma cells and the JNK pathway in patient 
derived xenograft glioblastoma cells. Finally, we realize the 
heightened interest in this research area, and we are cur-
rently preparing a review on the repurposing of antipsy-
chotic phenothiazines for the treatment of cancer and their 
mechanism(s) of actions and we will certainly include the 
suggestions made by Dr Yoshida. Indeed, chlorpromazine is 
one of the first phenothiazines that has been registered for a 
clinical trial for GBM and we will be tracking its progress. 
It is worth noting that the repurposing of chlorpromazine for 
Covid-19 treatment is also under investigation.
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